フランス企業Servierはデイワンバイオファーマを2.5億ドルで買収し,小児薬を含む珍しいがん治療の拡大を図る. French firm Servier buys Day One Biopharma for $2.5B to expand rare cancer treatments, including pediatric drugs.

フランス製薬会社Servierは,Day One Biopharmaceuticalsを25億ドルで現金で買収することに同意し,株当たり21.50ドル (68%のプレミアム) を支払った.これは,その珍しい腫瘍学パイプライン,特に小児がんの拡大のためだ. French pharmaceutical company Servier has agreed to acquire Day One Biopharmaceuticals for $2.5 billion in cash, paying $21.50 per share, a 68% premium, to expand its rare oncology pipeline, particularly in pediatric cancers. 2026年第2四半期に完了すると予想されるこの取引には,小児低度性膠原腫に対するFDA承認の薬Ojemdaと,固体腫瘍に対する第1段階プログラムを含む抗体薬コンジュガートのパイプラインが含まれています. The deal, expected to close in the second quarter of 2026, includes Day One’s FDA-approved drug Ojemda for pediatric low-grade glioma and its pipeline of antibody drug conjugates, including a Phase 1 program for solid tumors. Servierは,患者のアクセスを加速し,2030年までに年間販売で440億円の目標となるアトラス成長戦略の推進を目指す. Servier aims to leverage its global reach to accelerate patient access and advance its oncology growth strategy, which targets €4 billion in annual sales by 2030. デイ・ワン社の取締役会は取引を承認し, 発表後,株式は65.7%上昇した. Day One’s board has approved the transaction, and its shares surged 65.7% following the announcement.